Abbreviated quality of life scales for schizophrenia: Comparison and utility of two brief community functioning measures

Schizophrenia Research

Volumn 154, Issue 1-3, 2014, Pages 89-92

  Fervaha, Gagan ^a,b   Foussias, George ^a,b,c   Siddiqui, Ishraq ^a,b   Agid, Ofer ^a,b,c   Remington, Gary ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Abbreviated quality of life scale; Avolition apathy; Clinical assessment tool; Functional outcome; Psychosocial functioning; Schizophrenia

Indexed keywords

ADULT; AGED; ARTICLE; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY OF LIFE SCALE; RATING SCALE; SCHIZOPHRENIA; SYMPTOM ASSESSMENT; VALIDATION STUDY; ADOLESCENT; LONGITUDINAL STUDY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; QUALITY OF LIFE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 84897833146     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.02.013     Document Type: Article

References (29)

1. Addington D., Addington J., Schissel B. A depression rating scale for schizophrenics. Schizophr. Res. 1990, 3(4):247-251.
2. Bilker W.B., Brensinger C., Kurtz M.M., Kohler C., Gur R.C., Siegel S.J., Gur R.E. Development of an abbreviated schizophrenia quality of life scale using a new method. Neuropsychopharmacology 2003, 28(4):773-777.
3. Evensen J., Rossberg J.I., Barder H., Haahr U., Hegelstad W., Joa I., Johannessen J.O., Larsen T.K., Melle I., Opjordsmoen S., Rund B.R., Simonsen E., Sundet K., Vaglum P., Friis S., McGlashan T. Apathy in first episode psychosis patients: a ten year longitudinal follow-up study. Schizophr. Res. 2012, 136(1-3):19-24.
4. Faerden A., Friis S., Agartz I., Barrett E.A., Nesvag R., Finset A., Melle I. Apathy and functioning in first-episode psychosis. Psychiatr. Serv. 2009, 60(11):1495-1503.
5. Faerden A., Barrett E.A., Nesvag R., Friis S., Finset A., Marder S.R., Ventura J., Andreassen O.A., Agartz I., Melle I. Apathy, poor verbal memory and male gender predict lower psychosocial functioning one year after the first treatment of psychosis. Psychiatry Res. 2013, 210(1):55-61.
6. Fervaha G., Remington G. Validation of an abbreviated quality of life scale for schizophrenia. Eur. Neuropsychopharmacol. 2013, 23(9):1072-1077.
7. Fervaha G., Foussias G., Agid O., Remington G. Amotivation and functional outcomes in early schizophrenia. Psychiatry Res. 2013, 210(2):665-668.
8. Fervaha G., Graff-Guerrero A., Zakzanis K.K., Foussias G., Agid O., Remington G. Incentive motivation deficits in schizophrenia reflect effort computation impairments during cost-benefit decision-making. J. Psychiatr. Res. 2013, 47(11):1590-1596.
9. First M.B. User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders SCID-I: Clinician Version 1997, Amer Psychiatric Pub Inc., Washington, DC.
10. Fisher M., Holland C., Merzenich M.M., Vinogradov S. Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. Am. J. Psychiatry 2009, 166(7):805-811.
11. Foussias G., Mann S., Zakzanis K.K., van Reekum R., Agid O., Remington G. Prediction of longitudinal functional outcomes in schizophrenia: the impact of baseline motivational deficits. Schizophr. Res. 2011, 132(1):24-27.
12. Grant P.M., Beck A.T. Defeatist beliefs as a mediator of cognitive impairment, negative symptoms, and functioning in schizophrenia. Schizophr. Bull. 2009, 35(4):798-806.
13. Harvey P.D. Assessment of everyday functioning in schizophrenia: implications for treatments aimed at negative symptoms. Schizophr. Res. 2013, 150(2-3):353-355.
14. Harvey P.D., Sabbag S., Prestia D., Durand D., Twamley E.W., Patterson T.L. Functional milestones and clinician ratings of everyday functioning in people with schizophrenia: overlap between milestones and specificity of ratings. J. Psychiatr. Res. 2012, 46(12):1546-1552.
15. Heinrichs D.W., Hanlon T.E., Carpenter W.T. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 1984, 10(3):388-398.
16. Hill K., Startup M. The relationship between internalized stigma, negative symptoms and social functioning in schizophrenia: the mediating role of self-efficacy. Psychiatry Res. 2013, 206(2-3):151-157.
17. Hooker C.I., Bruce L., Lincoln S.H., Fisher M., Vinogradov S. Theory of mind skills are related to gray matter volume in the ventromedial prefrontal cortex in schizophrenia. Biol. Psychiatry 2011, 70(12):1169-1178.
18. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., Murray R.M., Markwick A., Lewis S.W. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 2006, 63(10):1079-1087.
19. Kaufman A.S. Should short-form validity coefficients be corrected?. J. Consult. Clin. Psychol. 1977, 45(6):1159.
20. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
21. Keefe R.S., Mohs R.C., Bilder R.M., Harvey P.D., Green M.F., Meltzer H.Y., Gold J.M., Sano M. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr. Bull. 2003, 29(1):45-55.
22. Keefe R.S., Bilder R.M., Harvey P.D., Davis S.M., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Miller D.D., Canive J.M., Adler L.W., Manschreck T.C., Swartz M., Rosenheck R., Perkins D.O., Walker T.M., Stroup T.S., McEvoy J.P., Lieberman J.A. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 2006, 31(9):2033-2046.
23. Kiang M., Christensen B.K., Remington G., Kapur S. Apathy in schizophrenia: clinical correlates and association with functional outcome. Schizophr. Res. 2003, 63(1-2):79-88.
24. Konstantakopoulos G., Ploumpidis D., Oulis P., Patrikelis P., Soumani A., Papadimitriou G.N., Politis A.M. Apathy, cognitive deficits and functional impairment in schizophrenia. Schizophr. Res. 2011, 133(1-3):193-198.
25. Kurtz M.M., Bronfeld M., Rose J. Cognitive and social cognitive predictors of change in objective versus subjective quality-of-life in rehabilitation for schizophrenia. Psychiatry Res. 2012, 200(2-3):102-107.
26. Leifker F.R., Patterson T.L., Heaton R.K., Harvey P.D. Validating measures of real-world outcome: the results of the VALERO expert survey and RAND panel. Schizophr. Bull. 2011, 37(2):334-343.
27. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353(12):1209-1223.
28. Matsui M., Sumiyoshi T., Arai H., Higuchi Y., Kurachi M. Cognitive functioning related to quality of life in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(1):280-287.
29. Stroup T.S., McEvoy J.P., Swartz M.S., Byerly M.J., Glick I.D., Canive J.M., McGee M.F., Simpson G.M., Stevens M.C., Lieberman J.A. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr. Bull. 2003, 29(1):15-31.